Revelation Biosciences Files 8-K
Ticker: REVBW · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $12,075.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, financials, filing
Related Tickers: REVB
TL;DR
REVB filed an 8-K on March 12, 2024, with updates on corporate events and financials.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on March 12, 2024, reporting on other events and financial statements. The company, formerly known as Petra Acquisition Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides updates on the company's corporate actions and financial status, which are important for investors to understand the company's current standing.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate events and financial statements, not indicating any immediate significant risks.
Key Numbers
- 001-39603 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-3898466 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- Petra Acquisition Inc. (company) — Former company name
- March 12, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego (location) — Business address city
FAQ
What is the primary purpose of this 8-K filing for Revelation Biosciences, Inc.?
The 8-K filing serves as a current report to disclose significant corporate events and financial information as of March 12, 2024.
When was Revelation Biosciences, Inc. previously known by another name?
Revelation Biosciences, Inc. was formerly known as Petra Acquisition Inc., with a name change occurring on April 23, 2020.
What industry does Revelation Biosciences, Inc. operate in?
Revelation Biosciences, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Revelation Biosciences, Inc. headquartered?
The company's business and mailing address is located at 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122.
What is the fiscal year end for Revelation Biosciences, Inc.?
The company's fiscal year ends on December 31st.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-11 21:53:19
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma
Filing Documents
- revb-20240312.htm (8-K) — 44KB
- revb-ex99_1.htm (EX-99.1) — 6KB
- revb-ex99_2.htm (EX-99.2) — 6KB
- revb-ex99_1s1.jpg (GRAPHIC) — 1648KB
- revb-ex99_2s1.jpg (GRAPHIC) — 329KB
- revb-ex99_2s2.jpg (GRAPHIC) — 664KB
- revb-ex99_2s3.jpg (GRAPHIC) — 557KB
- revb-ex99_2s4.jpg (GRAPHIC) — 474KB
- revb-ex99_2s5.jpg (GRAPHIC) — 531KB
- 0000950170-24-029611.txt ( ) — 6001KB
- revb-20240312.xsd (EX-101.SCH) — 48KB
- revb-20240312_htm.xml (XML) — 7KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 12, 2024, Revelation Biosciences, Inc. (the "Company") presented at the 29th International Conference on Advances in Critical Care Nephrology in San Diego, California. A copy of the poster and presentation is attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and is incorporated herein by reference. The information in Item 7.01 and in Exhibits 99.1 and 99.2 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Revelation Biosciences, Inc. Poster 99.2 Revelation Biosciences, Inc. Presentation 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: March 12, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)